Corbus Pharmaceuticals files $127.5 million at-the-market stock offering
Corbus set up a sale agreement with Jefferies LLC on August 7, 2026, allowing it to sell shares periodically to fund CRB-701 and CRB-913 development.
SEC filing
Latest
2 stories
Friday, August 7
Thursday, August 6
Corbus reports Q2 2026 results, clears FDA hurdle for CRB-701 trial
Corbus received FDA clearance to start a registrational study of its cancer drug CRB-701 while posting a wider quarterly net loss.
SEC filing